Edition:
United Kingdom

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

1.25USD
14 Dec 2017
Change (% chg)

$-0.12 (-9.09%)
Prev Close
$1.38
Open
$1.35
Day's High
$1.35
Day's Low
$1.23
Volume
69,932
Avg. Vol
30,732
52-wk High
$4.75
52-wk Low
$1.23

Latest Key Developments (Source: Significant Developments)

Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Titan Pharmaceuticals Inc ::TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING.TITAN PHARMACEUTICALS-‍PURSUANT TO AGREEMENT, CO WILL GRANT MOLTENI AN EXCLUSIVE RIGHT AND LICENSE TO COMMERCIALIZE PROBUPHINE IN EUROPEAN UNION​.TITAN PHARMACEUTICALS INC - ‍TITAN AND MOLTENI EXPECT TO ENTER INTO DEFINITIVE LICENSE AND DISTRIBUTION AGREEMENT DURING Q1 OF 2018​.  Full Article

Titan Pharmaceuticals Partners With Molteni To Market Probuphine In Europe
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Titan Pharmaceuticals Inc ::TITAN PHARMACEUTICALS PARTNERS WITH MOLTENI TO MARKET PROBUPHINE® IN EUROPE.TITAN PHARMACEUTICALS - ‍ENTERED BINDING TERM SHEET UNDER WHICH CO WILL GRANT MOLTENI EXCLUSIVE LICENSE TO COMMERCIALIZE PROBUPHINE IN EUROPEAN UNION​.TITAN PHARMACEUTICALS INC - ‍TITAN AND MOLTENI EXPECT TO ENTER INTO DEFINITIVE LICENSE AND DISTRIBUTION AGREEMENT DURING Q1 OF 2018​.TITAN PHARMACEUTICALS - TERM SHEET PROVIDES MOLTENI TO PAY CO UPFRONT, NON-REFUNDABLE LICENSE FEE OF EUR 2.0 MILLION UPON EXECUTION OF LICENSE DEAL​.  Full Article

Accepts Titan's Marketing Authorization Application For Probuphine®
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Titan Pharmaceuticals Inc ::EUROPEAN MEDICINES AGENCY ACCEPTS TITAN PHARMACEUTICALS' MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE®.TITAN PHARMACEUTICALS INC - ‍EUROPEAN MEDICINES AGENCY HAS ACCEPTED FOR REVIEW ITS MARKETING AUTHORIZATION APPLICATION FOR PROBUPHINE​.  Full Article

Titan Pharmaceuticals reports Q3 loss per share of $0.20
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Titan Pharmaceuticals Inc :Titan pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.20.‍Titan is evaluating potential funding options​.‍At Sept. 30, had cash and cash equivalents of about $11.7 million, which co believes is sufficient to fund planned operations through Aug 2018​.  Full Article

Titan Pharmaceuticals files for offering of up to 280,612 shares by selling stockholder
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Titan Pharmaceuticals Inc :Titan Pharmaceuticals Inc files for offering of up to 280,612 shares of co's common stock by the selling stockholder - SEC filing‍​.  Full Article

Titan Pharmaceuticals reports no license revenue for Q1 2016
Tuesday, 10 May 2016 

Titan Pharmaceuticals Inc : Reported no license revenue for q1 of 2016, compared with approximately $0.9 million for comparable period in 2015 . Titan Pharmaceuticals reports first quarter 2016 financial results .Q1 loss per share $0.09.  Full Article

BRIEF-Titan Pharmaceuticals Says Co​ Entered Into A Binding Term Sheet With L. Molteni & C. Dei F.Lli Alitti Societ*I Esercizio

* TITAN PHARMACEUTICALS INC - ON NOV 27, CO​ ENTERED INTO A BINDING TERM SHEET WITH L. MOLTENI & C. DEI F.LLI ALITTI SOCIET*I ESERCIZIO - SEC FILING